Glaukos Corporation
Research Glaukos Corporation (GKOS) on Bullrun: market cap USD 10.68B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGKOS
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 10.68B
- Financial periodQ2 2026
- RevenueUSD 185.61M
- Net income-USD 18.38M
- Free cash flowUSD 12.09M
- Gross margin81.7%
Valuation Snapshot
latest market cap is USD 10.68B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 507.44M | -USD 187.69M | -USD 22.46M | 55.7% | -3.28 | USD 90.81M | USD 103.88M | USD 656.16M |
| FY2024 | USD 383.48M | -USD 146.37M | -USD 67.62M | 75.5% | -2.77 | USD 169.63M | USD 103.40M | USD 766.93M |
| FY2023 | USD 314.71M | -USD 134.66M | -USD 78.01M | 76.0% | -2.78 | USD 93.47M | USD 383.74M | USD 461.77M |
| FY2022 | USD 282.86M | -USD 99.20M | -USD 63.35M | 75.6% | -2.09 | USD 119.53M | USD 382.54M | USD 530.01M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 10.68B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.49B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.46B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.88B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.08B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.09B | n/a | n/a | n/a |
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Glaukos Corporation's market cap?
Glaukos Corporation's market capitalization is USD 10.68B.
What does Glaukos Corporation do?
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.